164 related articles for article (PubMed ID: 36741385)
1. Lysine methyltransferase Kmt2d regulates naive CD8
Kim J; Nguyen T; Cifello J; Ahmad R; Zhang Y; Yang Q; Lee JE; Li X; Kai Y; De S; Peng W; Ge K; Weng NP
Front Immunol; 2022; 13():1095140. PubMed ID: 36741385
[TBL] [Abstract][Full Text] [Related]
2. Histone H3 lysine 4 methyltransferase KMT2D.
Froimchuk E; Jang Y; Ge K
Gene; 2017 Sep; 627():337-342. PubMed ID: 28669924
[TBL] [Abstract][Full Text] [Related]
3. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation.
Lee JE; Wang C; Xu S; Cho YW; Wang L; Feng X; Baldridge A; Sartorelli V; Zhuang L; Peng W; Ge K
Elife; 2013 Dec; 2():e01503. PubMed ID: 24368734
[TBL] [Abstract][Full Text] [Related]
4. Ezh2 Regulates Activation-Induced CD8
Chen G; Subedi K; Chakraborty S; Sharov A; Lu J; Kim J; Mi X; Wersto R; Sung MH; Weng NP
Front Immunol; 2018; 9():549. PubMed ID: 29632530
[TBL] [Abstract][Full Text] [Related]
5. H3K4me1 facilitates promoter-enhancer interactions and gene activation during embryonic stem cell differentiation.
Kubo N; Chen PB; Hu R; Ye Z; Sasaki H; Ren B
Mol Cell; 2024 May; 84(9):1742-1752.e5. PubMed ID: 38513661
[TBL] [Abstract][Full Text] [Related]
6. KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation.
Ang SY; Uebersohn A; Spencer CI; Huang Y; Lee JE; Ge K; Bruneau BG
Development; 2016 Mar; 143(5):810-21. PubMed ID: 26932671
[TBL] [Abstract][Full Text] [Related]
7. The epigenetic control of stemness in CD8
Pace L; Goudot C; Zueva E; Gueguen P; Burgdorf N; Waterfall JJ; Quivy JP; Almouzni G; Amigorena S
Science; 2018 Jan; 359(6372):177-186. PubMed ID: 29326266
[TBL] [Abstract][Full Text] [Related]
8. Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition.
Wang C; Lee JE; Lai B; Macfarlan TS; Xu S; Zhuang L; Liu C; Peng W; Ge K
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11871-11876. PubMed ID: 27698142
[TBL] [Abstract][Full Text] [Related]
9. KMT2D regulates activation, localization, and integrin expression by T-cells.
Potter SJ; Zhang L; Kotliar M; Wu Y; Schafer C; Stefan K; Boukas L; Qu'd D; Bodamer O; Simpson BN; Barski A; Lindsley AW; Bjornsson HT
Front Immunol; 2024; 15():1341745. PubMed ID: 38765012
[TBL] [Abstract][Full Text] [Related]
10. DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300.
Kim HJ; Moon SJ; Hong S; Won HH; Kim JH
Nucleic Acids Res; 2022 Aug; 50(14):7873-7888. PubMed ID: 35801925
[TBL] [Abstract][Full Text] [Related]
11. KMT2D deficiency disturbs the proliferation and cell cycle activity of dental epithelial cell line (LS8) partially via Wnt signaling.
Pang L; Tian H; Gao X; Wang W; Wang X; Zhang Z
Biosci Rep; 2021 Nov; 41(11):. PubMed ID: 34724040
[TBL] [Abstract][Full Text] [Related]
12. Mll3 and Mll4 Facilitate Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4 Monomethylation.
Dorighi KM; Swigut T; Henriques T; Bhanu NV; Scruggs BS; Nady N; Still CD; Garcia BA; Adelman K; Wysocka J
Mol Cell; 2017 May; 66(4):568-576.e4. PubMed ID: 28483418
[TBL] [Abstract][Full Text] [Related]
13. Loss of Histone Methyltransferase KMT2D Attenuates Angiogenesis in the Ischemic Heart by Inhibiting the Transcriptional Activation of VEGF-A.
Meng XM; Liu SB; Deng T; Li DY; You L; Hong H; Feng QP; Zhu BM
J Cardiovasc Transl Res; 2023 Oct; 16(5):1032-1049. PubMed ID: 36947365
[TBL] [Abstract][Full Text] [Related]
14. Kabuki syndrome stem cell models reveal locus specificity of histone methyltransferase 2D (KMT2D/MLL4).
Jefri M; Zhang X; Stumpf PS; Zhang L; Peng H; Hettige N; Theroux JF; Aouabed Z; Wilson K; Deshmukh S; Antonyan L; Ni A; Alsuwaidi S; Zhang Y; Jabado N; Garcia BA; Schuppert A; Bjornsson HT; Ernst C
Hum Mol Genet; 2022 Oct; 31(21):3715-3728. PubMed ID: 35640156
[TBL] [Abstract][Full Text] [Related]
15. EBF2 Links KMT2D-Mediated H3K4me1 to Suppress Pancreatic Cancer Progression via Upregulating KLLN.
Yao B; Xing M; Meng S; Li S; Zhou J; Zhang M; Yang C; Qu S; Jin Y; Yuan H; Zen K; Ma C
Adv Sci (Weinh); 2024 Jan; 11(2):e2302037. PubMed ID: 38015024
[TBL] [Abstract][Full Text] [Related]
16. Histone methyltransferase KMT2D inhibits ENKTL carcinogenesis by epigenetically activating SGK1 and SOCS1.
Zhang YH; Tao Q; Zhang WY; Zhao S; Liu WP; Gao LM
Genes Genomics; 2024 Feb; 46(2):203-212. PubMed ID: 37523130
[TBL] [Abstract][Full Text] [Related]
17. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Alam H; Tang M; Maitituoheti M; Dhar SS; Kumar M; Han CY; Ambati CR; Amin SB; Gu B; Chen TY; Lin YH; Chen J; Muller FL; Putluri N; Flores ER; DeMayo FJ; Baseler L; Rai K; Lee MG
Cancer Cell; 2020 Apr; 37(4):599-617.e7. PubMed ID: 32243837
[TBL] [Abstract][Full Text] [Related]
18. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription.
Wang SP; Tang Z; Chen CW; Shimada M; Koche RP; Wang LH; Nakadai T; Chramiec A; Krivtsov AV; Armstrong SA; Roeder RG
Mol Cell; 2017 Jul; 67(2):308-321.e6. PubMed ID: 28732206
[TBL] [Abstract][Full Text] [Related]
19. Histone Methyltransferase KMT2D Regulates H3K4 Methylation and is Involved in the Pathogenesis of Ovarian Cancer.
Li M; Shi M; Xu Y; Qiu J; Lv Q
Cell Transplant; 2021; 30():9636897211027521. PubMed ID: 34705580
[TBL] [Abstract][Full Text] [Related]
20. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Maitituoheti M; Keung EZ; Tang M; Yan L; Alam H; Han G; Singh AK; Raman AT; Terranova C; Sarkar S; Orouji E; Amin SB; Sharma S; Williams M; Samant NS; Dhamdhere M; Zheng N; Shah T; Shah A; Axelrad JB; Anvar NE; Lin YH; Jiang S; Chang EQ; Ingram DR; Wang WL; Lazar A; Lee MG; Muller F; Wang L; Ying H; Rai K
Cell Rep; 2020 Oct; 33(3):108293. PubMed ID: 33086062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
